Bipolar Disorder Market Size, Share By Disorder (Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder), By Drug Class (Mood Stabilizer, Anticonvulsant, Antipsychotic Drugs, Antidepressant Drugs, and Antianxiety Drugs), By Mechanism of Action (Serotonin-Norepinephrine Reuptake Inhibitors, Selective Serotonin Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, Beta Blockers, and Benzodiazepines), By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI101619 | Publish Date: April 2024 | No. of Pages: 182

Global Bipolar Disorder Market Market Companies

  • AstraZeneca limited.
  • Pfizer Inc.
  • Glaxo SmithKline (GSK)
  • Eli Lilly Inc.
  • Janssen Pharmaceuticals
  • Novartis AG pharmaceutical limited
  • Allergan Plc
  • Otsuka Holdings Co. Ltd.
  • AbbVie Inc.

Recent News:

  • Bristol Myers Squibb has established a goal launch plan for a "multi-billion-dollar opportunity" that will take place in January 2024 with the help of the schizophrenia medicine Karuna. This illness is undertreated and has few therapy options because it is still a serious but typically infrequent disease. While many older generics are still available, Lundbeck and Otsuka's Rexulti and other manufacturers hope to profit from the sales of additional illnesses like bipolar disorder and senile agitation.
  • Bukwang Pharmaceutical created a new CNS division in April 2024 ahead of the launch of a new medication. Bukwang Pharmaceutical announced the creation of a new division devoted to the central nervous system in anticipation of the later this year release of its new medication for schizophrenia and bipolar disorder, Latuda (ingredient: lurasidone hydrochloride).